HERCULES, Calif. — February 2, 2026 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced it has received validation from AOAC International for its EZ-Check Listeria spp. and EZ-Check Listeria monocytogenes Kits for the detection of Listeria spp. and Listeria monocytogenes in food products and environmental samples.
Listeria are gram-positive bacteria responsible for causing listeriosis. Primarily found in soil, water, and animal products, accurate detection of contamination in both food and environmental samples is critical in ensuring the production of safe consumables. Even with strict safety controls, contamination can still occur, posing health risks, costly recalls, and potential damage to brand reputation.
Bio-Rad’s ready-to-use, next-generation EZ-Check Listeria spp. and EZ-Check Listeria monocytogenes Kits deliver streamlined workflows with rapid time to results. Featuring multiplex amplification of the target pathogen and a critical internal control to monitor for false negatives, the proprietary, patented duplex detection system enhances accuracy and simplifies reaction set-up.
“Listeriosis is a serious infection that can be life threatening for pregnant women, children, and individuals with weakened immune systems, meaning accurate detection is of the utmost importance,” said Dr. Jesse Miller, Associate Director of Marketing, Food Science Division, Bio-Rad Laboratories. “The EZ-Check real-time PCR product range provides a premium and simple workflow, enabling rapid, reliable detection of key organisms. AOAC validation of the EZ-Check Listeria spp. and EZ-Check Listeria monocytogenes Kits further demonstrates our established position as leaders in food safety testing, delivering effective solutions for pathogen detection in food and environmental samples”.
For more information on Bio-Rad’s EZ-Check Kits, visit bio-rad.com/EZCheck.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 7,500 employees, and $2.6 billion in revenues in 2024. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com.
Forward-Looking Statements
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our products and our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include risks relating to our international operations, global economic and geopolitical conditions, tariffs or other trade barriers, reductions in government funding or capital spending of our customers, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, supply chain risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad's public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
Media Contacts:
Bio-Rad Laboratories, Inc.
Wendy Lauer
wendy_lauer@bio-rad.com
Zyme Communications
Francesca Wallace
+447506 424 870
Francesca.wallace@zymecommunications.com
To opt-out from receiving press releases from Zyme Communications please email info@zymecommunications.com. To view our privacy policy please click here.